Dr. David Fajgenbaum

identify about, I think it's about 60 or 70 right now that have gotten what we call a deep dive where an MD or a PhD or an MD PhD trained person will really try to understand what are all the data for or against, like why would this drug likely work or not work?

And then out of those 60 or so who have done deep dives, about 15 of those have then basically taken down to where we have a good plan.

We think that if we do this clinical trial, we're gonna be able to unlock this drug helping a lot of kids or adults.

And then out of those, I mentioned now like the nine active programs that we're moving forward.

So we started as a non-private three years ago.

We spent most of our first year doing fundraising, most of our second year really building on our infrastructure.

It's really only been about one year where we've had the team working hard, going through all these scores.

And so the opportunities I think are so huge.

How do you find the patients to do the studies on?

Yeah, so once we find a match that we think looks really promising, the next thing we do is find out who are the disease experts and who are the doctors that see the most patients?

Is there a disease group?

For a lot of these diseases, there's a parent of a kid with a disease where they've rallied around and created a nonprofit for that disease.

We want to get in touch with them and understand their disease more.

We want to understand what's missing.

Could this drug really make a difference?

And when we connect with them, it's like, we want to help your kid's condition or your condition.

You know, will you work with us?

You know, we've raised money from the U.S.

government and from philanthropists and foundations.

You know, we're going to bring some money into here.